HIV 1 News and Research

RSS

Arginine methylation important in SARS-CoV-2 viral replication

Researchers show that methylation of arginine in the virus nucleocapsid protein controls the protein's functions and plays a role in the life cycle of the SARS-CoV-2 virus.

29 Mar 2021

Developing a COVID-19 vaccine using inactivated E. coli

A team of researchers inactivated whole-cell E.coli with a reduced genome and utilized this to express coronavirus-specific fusion peptides, demonstrating a potent anamnestic response.

19 Mar 2021

Researchers explore nanotechnology’s potential to deliver synergistic therapeutics for COVID-19

A team of scientists reviewed the nanoencapsulation approaches of synergistic compounds (Lectins, Caffeine, Cocoa, Flavonoids, Quercetin) and the role of nanotechnology in addressing the COVID-19 pandemic.

19 Mar 2021

New Phase 1 study evaluates prime/boost HIV-1 vaccine formulated with combinations of adjuvants

A new Phase 1 vaccine study began today that will evaluate experimental prime/boost HIV-1 vaccine regimens formulated with combinations of different adjuvants, including one from the Army Liposome Formulation (ALF) family of adjuvants developed by scientists with the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

15 Mar 2021

Scientists increase potency of HIV-1 antibody, identify new ways to develop vaccines

Much like coronavirus, circulating HIV-1 viruses mutate into diverse variants that pose challenges for scientists developing vaccines to protect people from HIV/AIDS.

12 Mar 2021

Neutralizing antibodies may be evolving to keep up with SARS-CoV-2 mutations

Viruses evolve under increased pressure, and new research from The Rockefeller University and University of Massachusetts Medical School in the U.S. suggests our antibodies can as well.

10 Mar 2021

Research shows effective strategy to target the SARS-CoV-2 spike protein

The virus that causes COVID-19 belongs to the family of coronaviruses, "corona" referring to the spikes on the viral surface. These spikes are not static-;to infect cells, they change shapes.

25 Feb 2021

Cannabinoid receptor agonist shows potential protective effect on SARS-CoV-2-infected human heart cells

As scientists continue to search for effective antidotes to direct and indirect damage caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server demonstrates the potential of cannabinoid receptor agonists to alleviate myocardial damage in this condition even in the absence of any inhibitory effect on viral infection as such.

23 Feb 2021

Researchers use high-resolution imaging to observe HIV infection process in the cell nucleus

Scientists at EMBL Heidelberg and at the Zentrum für Infektiologie at Heidelberg University Hospital have succeeded for the first time in imaging HIV during transport into the nucleus of an infected cell.

18 Feb 2021

Are antibody cocktails the key to COVID-19 treatment?

News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.

18 Feb 2021

HIV: New therapeutic approach to restore the effectiveness of immune cells

Prompted by the need to improve conventional treatments for people infected with the human immunodeficiency virus (HIV-1), a team from the Institut national de la recherche scientifique has identified a therapeutic approach to restore the effectiveness of immune cells.

8 Feb 2021

SHREK proteins mediate broad spectrum antiviral host immunity, including against SARS-CoV-2

A new preprint posted to the bioRxiv server demonstrates that similar mucins and mucin-like proteins cannot only suppress HIV-1 infectivity via blockage of viral attachment to the host cells but can block infection by multiple enveloped viruses.

4 Feb 2021

Phase 1 clinical trial of novel HIV vaccine approach shows promising results

A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today.

3 Feb 2021

FDA approves first injectable, complete regimen for HIV-1 infection in adults

The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

21 Jan 2021

Carbon-based nanomaterials as potential COVID-19 treatments

An international team of researchers says that carbon-based nanomaterials (CBNs) could represent promising new approaches to treating coronavirus disease 2019 (COVID-19) pneumonia that is complicated by a secondary bacterial, viral or fungal infection.

19 Jan 2021